# QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

> **NCT02559674** · PHASE1 · COMPLETED · sponsor: **Altor BioScience** · enrollment: 8 (actual)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Gemcitabine
- **BIOLOGICAL:** Nab-paclitaxel
- **BIOLOGICAL:** ALT-803

## Key facts

- **NCT ID:** NCT02559674
- **Lead sponsor:** Altor BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-02-21
- **Final completion:** 2018-02-21
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559674, "QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02559674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*